Motility é um ativo inovador de origem natural que age no tratamento da constipação através da modulação do eixo intestino-cérebro. De acordo com estudos, Motility trabalha de forma direcional atuando no equilíbrio do cortisol, serotonina e gastrina através da sinergia de seus ativos que ajudam a reestabelecer a motilidade intestinal, contribuindo para regulação das evacuações de forma natural sem a necessidade de efeitos laxativos, além de contribuir para a microbiota intestinal.

Estudos comprovam que o Motility pode promover evacuações completas de 3 a 7 vezes por semana de forma fisiológica sem causar os efeitos colaterais dos laxantes, desconfortos ou irritação ao epitélio intestinal.

Benefícios:

·    Ajuda na melhora da constipação crônica ou ocasional sem os efeitos colaterais laxativos;

·    Contribui para melhora da digestão e a absorção de nutrientes;

·    Auxilia na regularização do trânsito intestinal e evacuação completa;

·    Ajuda a reduzir os sintomas de refluxo, indigestão e cólicas intestinais;

·    Auxílio no equilíbrio da microbiota intestinal;

·    Melhora sensação de bem-estar.

Recomendações de uso: 300mg a 500 mg - Uma vez ao dia preferencialmente a noite.

Saiba mais sobre MOTILITY clicando em:  https://www.infinitypharma.com.br/produto/motility/

IMPORTANTE:

As informações desta postagem possuem caráter informativo apenas e não devem ser usadas para automedicação. Consulte sempre um prescritor da área da saúde.

Manter fora do alcance das crianças. Conservar em local fresco, seco e ao abrigo da luz solar.

AO PERSISTIREM OS SINTOMAS, UM MÉDICO DEVERA SER CONSULTADO.

Referências:

1.Zhao Y, Yu YB. Intestinal microbiota and chronic constipation. Springerplus. 2016;5(1):1130. doi:10.1186/s40064-016-2821-1. 2. Xu Z, Liu T, Zhou Q, Chen J, Yuan J, Yang Z. Roles of chinese medicine and gut microbiota in chronic constipation. Evid Based Complement Alternat Med. 2019;2019:9372563–11. doi:10.1155/2019/9372563. 3. Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020;158(5):1232–49.e3. doi:10.1053/j.gastro.2019.12.034. 4. Zheng H, Chen Q, Chen M, Wu X, She TW, Li J, Huang DQ, Yue L, Fang JQ. Nonpharmacological conservative treatments for chronic functional constipation: a systematic review and network meta-analysis. Neurogastroenterol Motil. 2019;31(1):e13441. doi:10.1111/nmo.13441. 5. Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. Gastroenterology. 2016;18: s 0016–5085(16)00222-5. doi:10.1053/j.gastro.2016.02.031. 6. Shin JE, Jung HK, Lee TH, Jo Y, Lee H, Song KH, Hong SN, Lim HC, Lee SJ, Chung SS, et al. Guidelines for the diagnosis and treatment of chronic functional constipation in Korea, 2015 Revised Edition. J Neurogastroenterol Motil. 2016;22(3):383–411. doi:10.5056/jnm15185. 7. Wang F, Fei M, Hu WZ, Wang XD, Liu S, Zeng Y, Zhang JH, Lv Y, Niu JP, Meng XL, et al. Prevalence of constipation in elderly and its association with dementia and mild cognitive impairment: a cross-sectional study. Front Neurosci. 2021;15:821654. doi:10.3389/ fnins.2021.821654. 8. Staller K, Olén O, Söderling J, Roelstraete B, Törnblom H, Song M, Ludvigsson JF. Chronic constipation as a risk factor for colorectal cancer: results from a nationwide, case-control study. Clin Gastroenterol Hepatol. 2022;20(8):1867–76.e2.doi:10.1016/j.cgh.2021.10.024.9. Wu L, Wu H, Huang F, Li X-y, Zhen Y-h, Zhang B-f, Li H-y Causal association between constipation and risk of colorectal cancer: a bidirectional twosample Mendelian randomization study. Front Oncol. 2023;13:1282066. doi:10.3389/fonc.2023.1282066. 10. Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664– 74. doi:10.1016/S0140-6736(20)32115-2. 11. Voderholzer WA, Schatke W, Mühldorfer BE, Klauser AG, Birkner B, Müller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol. 1997;92(1):95–8. 12. Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebocontrolled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102(7):1436–41. doi:10.1111/j.1572-0241.2007.01199.x. 13. Zhao Q, Chen Y-Y, Xu D-Q, Yue S-J, Fu R-J, Yang J, Xing L-M, Tang Y-P. Action mode of gut motility, fluid and electrolyte transport in chronic constipation. Front Pharmacol. 2021;12:630249. doi:10.3389/fphar.2021.630249. 14. Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, Bochenek W, Tripp K, Currie MG, Fox SM, et al. Low-dose linaclotide (72µg) for chronic idiopathic constipation: a 12-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2018;113(1):105–14. doi:10.1038/ajg.2017.230. 15. Guzel T, Mirowska-Guzel D. The role of serotonin neurotransmission in gastrointestinal tract and pharmacotherapy. Molecules. 2022;27(5):1680. doi:10.3390/molecules27051680. 16. Keefer L. Behavioural medicine and gastrointestinal disorders: the promise of positive psychology. Nat Rev Gastroenterol Hepatol. 018;15(6):378–86. doi:10.1038/s41575-018- 0001-1. 17. Feng J, Zheng N, Fan X, Li S, Jiang Y, Yi X, Yang H. Association of laxatives use with incident dementia and modifying effect of genetic susceptibility: a population-based cohort study with propensity score matching. BMC Geriatr. 2023;23(1):122.  doi:10.1186/ s12877-023-03854-w. 18. Müller-Lissner S, Tack J, Feng Y, Schenck F, Specht Gryp R. Levels of satisfaction with current chronic constipation treatment options in Europe - an internet survey. Aliment Pharmacol Ther. 2013;37(1):137–45. doi:10.1111/apt.12124. 19. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599–608. doi:10.1111/j.1365-2036.2006.03238.x. 20. Punukollu RS, Chadalawada AK, Siddabattuni K, Gogineni NT. A blend of Withania somnifera (L.) Dunal root and Abelmoschus esculentus (L.) Moench fruit extracts relieves constipation and improves bowel function: a proof-of-concept clinical investigation. J Ethnopharmacol. 2024;318(Pt B):116997. doi:10.1016/j.jep.2023.116997. 21. Smith SJ, Lopresti AL, Fairchild TJ. Exploring the efficacy and safety of a novel standardized ashwagandha (Withania somnifera) root extract (Witholytin®) in adults experiencing high stress and fatigue in a randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2023;37(11):1091–104. doi:10.1177/02698811231200023. 22. Islam MT. Phytochemical information and pharmacological activities of Okra (Abelmoschus esculentus): a literature-based review. Phytother Res. 2019;33(1):72–80. doi:10.1002/ptr.6212. 23. Chandran U, Patwardhan B. Network ethnopharmacological evaluation of the immunomodulatory activity of Withania somnifera. J Ethnopharmacol. 2017;197:250–6. doi:10.1016/j.jep.2016.07.080. 24. Mohanty I, Arya DS, Dinda A, Talwar KK, Joshi S, Gupta SK. Mechanisms of cardioprotective effect of Withania somnifera in experimentally induced myocardial infarction. Basic Clin Pharmacol Toxicol. 2004;94(4):184–90. doi:10.1111/j.1742- 7843.2004.pto940405.x. 25. Choudhary B, Shetty A, Langade DG. Efficacy of Ashwagandha (Withania somnifera [L.] Dunal) in improving cardiorespiratory endurance in healthy athletic adults. Ayu. 2015;36(1):63–8. doi:10.4103/0974-8520.169002. 26. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5(4):334–46. 27. Glotter E. Withanolides and related ergostane-type steroids. Nat Prod Rep. 1991;8(4):415–40. doi:10.1039/np9910800415. 28. Tomar V, Beuerle T, Sircar D. A validated HPTLC method for the simultaneous quantifications of three phenolic acids and three withanolides from Withania somnifera plants and its herbal products. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1124:154– 60.doi:10.1016/j.jchromb.2019.06.009. 29. Kumar A, Kumar P, Nadendla R. A review on: abelmoschus esculentus (Okra). International Research Journal of Pharmaceutical and Applied Sciences. 2013;3(4):129–32 30. Ahiakpa JK, Amoatey HM, Amenorpe G, Apatey J, Ayeh EA, Agbemavor WS. Mucilage content of 21 accessions of Okra (Abelmoschus spp L.). Scientia Agriculturae. 2014;2(2):96–101. doi:10.15192/PSCP.SA.2014.2.2.96101.